Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
  • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
  • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
  • C07D279/18—[b, e]-condensed with two six-membered rings

Definitions

• the present invention provides compositions and methods for preventing and treating viral infections.
• the present invention thus has applications in the areas of medicine, pharmacology, virology, and medicinal chemistry.
• Punta Toro Virus Punta Toro Virus
• WNV West Nile virus
• CHK chikungunya virus
• EEEV Easter Equine Encephalitis virus
• WEEV Wester Equine Encephalitis virus
• Lhasa virus LASV
• DENV Dengue virus
• Venezuelan Equine Encephalitis virus also called Venezuelan equine encephalomyelitis
• VEEV a mosquito-borne viral disease of all equine species, including horses, asses (wild and domestic), and zebras. Equines infected with VEEV may show one or more of the following signs: fever, depression, loss of appetite weakness, and central nervous system disorders (lack of coordination, chewing movements, head pressing, "sawhorse” stance, circling, paddling motion of the limbs, and convulsions). In some cases, horses infected with VEEV may show no clinical signs before dying. The clinical signs of VEEV can be confused with those of other diseases that affect the central nervous system.
• VEE might also be mistaken for toxic poisoning. Definitive diagnosis can be made by isolating the virus in a laboratory or by testing blood for the presence of antibodies to the virus.
• the virus that causes VEEV is transmitted primarily by mosquitoes that bite an infected animal and then bite and feed on another animal or human.
• the speed with which the disease spreads depends on the subtype of the VEEV virus and the density of mosquito populations.
• Enzootic subtypes of VEEV are diseases endemic to certain areas. Generally these serotypes do not spread to other localities. Enzootic subtypes are associated with the rodent-mosquito transmission cycle. These forms of the virus can cause human illness but generally do not affect equine health.
• Epizootic subtypes can spread rapidly through large populations. These forms of the virus are highly pathogenic to equines and can also affect human health.
• Equines rather than rodents, are the primary animal species that carry and spread the disease. Infected equines develop an enormous quantity of virus in their circulatory system. When a blood- feeding insect feeds on such animals, it picks up this virus and transmits it to other animals or humans. Although other animals, such as cattle, swine, and dogs, can become infected, they generally do not show signs of the disease or contribute to its spread.
• VEEV Naturally occurring outbreaks of VEEV are rare.
• VEEV was first recognized as a disease of concern in Venezuela following a major outbreak of equine encephalomyelitis. From 1936 to 1968, equines in several South American countries suffered devastating outbreaks. In 1969, the disease moved north throughout Central America, finally reaching Mexico and Texas in 1971. The highly pathogenic form of VEEV has not occurred in the United States since 1971. However, in 1993 an outbreak of VEEV in the
• West Nile virus Similar to VEE is West Nile virus (“WNV”), which was mentioned above. West Nile virus is named for a district in Kenya where the virus was first identified in humans in 1937. Outbreaks of the virus have occurred in a number of countries throughout Europe, the Middle East, Africa, Central Asia, and Australia, since that time. WNV was first detected in the Western Hemisphere in 1999, and since then the disease has spread across North America, Mexico, Puerto Rico, the Dominican Republic, Jamaica, Guadeloupe, and El Salvador. Symptoms range from a mild, flulike illness (fever, headache, muscle and joint pain) and a red, bumpy rash, to meningitis. In rare cases those infected will develop encephalitis, which can include high fever, a stiff neck, disorientation, paralysis, convulsions, coma, and death in about 10 percent of cases.
• the present invention provides novel anti-viral compounds and methods for preventing and treating viral infections.
• the compounds and methods provided by the invention are active against a broad range of virus families; and the compounds and methods of the invention have activity as broad-spectrum anti- viral therapies.
• the present invention provides a compound having the structure:
• R 1 and R 2 are selected independently from the group consisting of: hydrogen, halo, cyano, carbonyl, carboxyl, and optionally substituted lower alkyl, optionally substituted lower alkyloxy, and optionally substituted lower alkylcarbonyl.
• R 3 -R 6 are selected independently from the group consisting of: optionally substituted lower alkyl and lower hydroxyalkyl, and further R 3 and R 4 , and R 5 and Re, together with the nitrogens to which they are attached respectively, may form independently an optionally substituted saturated or unsaturated five- or six-membered ring.
• R 3 -Rg is substituted or unsubstituted C 1 ⁇ alkyl, substituted or unsubstituted C 2 - A alkenyl when both R 1 and R 2 are selected from the group consisting of hydrogen, Q_ 4 alkyl, C 2 ⁇ alkenyl, or halogenated C 1 ⁇ alkyl; and none of R 3 -R 6 , together with the nitrogens to which they are attached respectively, forms piperazin-1-yl when both R 1 and R 2 are hydrogen.
• At least one OfR 1 and R 2 is hydrogen, and , in more specific embodiments of the foregoing, both R 1 and R 2 are hydrogen.
• at least one OfR 3 -R 6 ' together with the nitrogens to which they are attached respectively, is an optionally substituted saturated or unsaturated five- or six-membered ring; in more specific embodiments of the foregoing, the aforementioned five- or six- membered ring is saturated. Still more specific embodiments are those in which the aforementioned saturated five- or six-membered ring is a five-membered ring. In yet more specific embodiments, the aforementioned saturated five-membered ring is pyrrolyl.
• the invention provides the novel compounds shown below and their pharmaceutically acceptable salts, hydrates, and complexes:
• the present invention provides a method for treating an animal infected with a virus, comprising administering to such animal a therapeutically effective amount of a compound having the structure:
• Ri and R 2 are selected independently from the group consisting of: hydrogen, halogen, cyano, carbonyl, carboxyl, and optionally substituted lower alkyl, optionally substituted lower alkyloxy, and optionally substituted lower alkylcarbonyl.
• R 3 -R 6 are selected independently from the group consisting of: optionally substituted lower alkyl and lower hydroxyalkyl, and further R 3 and R 4 , and R 5 and R 6 , together with the nitrogens to which they are attached respectively, may form independently an optionally substituted saturated or unsaturated five- or six-membered ring.
• the virus is selected from the group consisting of: HCV, VEEV, RVFV, LASV, and EBOV.
• Figures IA and IB illustrate a study in which a compound of the invention was tested for its ability to protect mice from Ebola (EBOV) infection.
• Figure IA shows the results for the control group.
• Figure IB shows the results for the study group.
• Figures 2 A and 2B illustrate a study in which a compound of the invention was tested for its ability to protect mice from Marburg virus infection.
• Figure 2A shows the results for the control group.
• Figure 2B shows the results for the study group.
• Optionally substituted refers to the replacement of hydrogen with a monovalent or divalent radical.
• Suitable substitution groups include, for example, hydroxyl, nitro, amino, imino, cyano, halo, thio, thioamido, amidino, oxo, oxamidino, methoxamidino, imidino, guanidino, sulfonamido, carboxyl, formyl, loweralkyl, haloloweralkyl, loweralkoxy, haloloweralkoxy, loweralkoxyalkyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroaralkylcarbonyl, alkylthio, aminoalkyl, cyanoalkyl, and the like.
• the substitution group can itself be substituted.
• the group substituted onto the substitution group can be, for example, carboxyl, halo; nitro, amino, cyano, hydroxyl, loweralkyl, loweralkoxy, aminocarbonyl, -SR, thioamido, -SO 3 H, -SO 2 R or cycloalkyl, where R is typically hydrogen, hydroxyl or loweralkyl.
• the substituted substituent includes a straight chain group, the substitution can occur either within the chain (e.g., 2-hydroxypropyl, 2-aminobutyl, and the like) or at the chain terminus (e.g. 2-hydroxyethyl, 3-cyanopropyl, and the like).
• Substituted substitutents can be straight chain, branched or cyclic arrangements of covalently bonded carbon or heteroatoms.
• Loweralkyl refers to branched or straight chain alkyl groups comprising one to ten carbon atoms that independently are unsubstituted or substituted, e.g., with one or more halogen, hydroxyl or other groups.
• loweralkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n- butyl, t-butyl, n-hexyl, neopentyl, trifluoromethyl, pentafluoroethyl, and the like.
• Alkyl refers to a divalent straight chain or branched chain saturated aliphatic radical having from 1- to 20 carbon atoms. Typical alkyl groups employed in compounds of the present invention are loweralkylenyl groups that have from 1 to about 6 carbon atoms in their backbone. "Alkenyl” refers herein to straight chain, branched, or cyclic radicals having one or more double bonds and from 2- to 20 carbon atoms. “Alkynyl” refers herein to straight chain, branched, or cyclic radicals having one or more triple bonds and from 2- to
• haloloweralkyl refers to a loweralkyl radical substituted with one or more halogen atoms.
• Loweralkoxy refers to RO- wherein R is loweralkyl.
• Representative examples of loweralkoxy groups include methoxy, ethoxy, ⁇ -butoxy, trifluoromethoxy and the like.
• “Loweralkythio” as used herein refers to RS- wherein R is loweralkyl.
• alkoxyalkyl refers to the group ⁇ Ik 1 -OaIk 2 where alkiis alkylenyl or alkenyl, and alk 2 is alkyl or alkenyl.
• loweralkoxyalkyl refers to an alkoxyalkyl where alkiis loweralkylenyl or loweralkenyl, and alk 2 is loweralkyl or loweralkenyl.
• aryloxyalkyl refers to the group -alkylenyl- O-aryl.
• aralkoxyalkyl refers to the group -alkylenyl-O-aralkyl, where aralkyl is a loweraralkyl.
• Cycloalkyl refers to a mono- or polycyclic, loweralkyl substituent. Typical cycloalkyl substituents have from 3- to 8 backbone (i.e., ring) atoms in which each backbone atom is optionally substituted carbon. When used in context with cycloalkyl substituents, the term “polycyclic” refers herein to fused, non-fused cyclic carbon structures and spirocycles. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, bornyl, norbornyl, and the like.
• cycloheteroalkyl refers herein to cycloalkyl substituents that have from 1 to 5, and more typically from 1 to 4 heteroatoms (i.e., non-carbon atoms such as nitrogen, sulfur, and oxygen) in the ring structure, with the balance of atoms in the ring being optionally substituted carbon.
• Representative heterocycloalkyl moieties include, for example, morpholino, piperazinyl, piperidinyl, pyrrolidinyl, methylpryolidinyl, pyrrolidinone-yl, and the like.
• the terms "(cycloalkyl)alkyl” and “(cycloheteroalkyl)alkyl” refer to alkyl chains substituted with cycloalkyl and cycloheteroalkyl groups respectively.
• haloalkoxy refers to an alkoxy radical substituted with one or more halogen atoms.
• haloloweralkoxy refers to a loweralkoxy radical substituted with one or more halogen atoms.
• Halo refers herein to a halogen radical, such as fluorine, chlorine, bromine, or iodine.
• Aryl refers to monocyclic and polycyclic aromatic groups, or fused ring systems having at least one aromatic ring, having from 3- to 14 backbone carbon atoms.
• aryl groups include without limitation phenyl, naphthyl, dihydronaphtyl, tetrahydronaphthyl, and the like.
• Aralkyl refers to an alkyl group substituted with an aryl group. Typically, aralkyl groups employed in compounds of the present invention have from 1- to 6 carbon atoms incorporated within the alkyl portion of the aralkyl group. Suitable aralkyl groups employed in compounds of the present invention include, for example, benzyl, picolyl, and the like.
• heteroaryl refers herein to aryl groups having from one to four heteroatoms as ring atoms in an aromatic ring with the remainder of the ring atoms being aromatic or non-aromatic carbon atoms.
• polycyclic refers herein to fused and non-fused cyclic structures in which at least one cyclic structure is aromatic, such as, for example, benzodioxozolo, naphthyl, and the like.
• heteroaryl moieties employed as substituents in compounds of the present invention include pyridyl, pyrimidinyl, thiazolyl, indolyl, imidazolyl, oxadiazolyl, tetrazolyl, pyrazinyl, triazolyl, thiophenyl, furanyl, quinolinyl, purinyl, benzothiazolyl, benzopyridyl, and benzimidazolyl, and the like.
• Amino refers herein to the group -NH 2 .
• loweralkylamino refers herein to the group -NRR' where R and R' are each independently selected from hydrogen or loweralkyl.
• arylamino refers herein to the group -NRR' where R is aryl and R' is hydrogen, loweralkyl, aryl, or aralkyl.
• aralkylamino refers herein to the group -NRR' where R is aralkyl and R' is hydrogen, loweralkyl, aryl, or aralkyl.
• aminocarbonyl refers herein to the group -C(O)-NH 2 .
• loweralkylaminocarbonyl arylaminocarbonyl
• aralkylaminocarbonyl aralkylaminocarbonyl
• heteroarylaminocarbonyl aralkylaminocarbonyl
• heteroarylaminocarbonyl aralkylaminocarbonyl
• thio refers to -SH.
• loweralkylthio refers to -SH.
• arylthio refers to -SH.
• heteroarylthio refers to -SH.
• cycloalkylthio refers to -SH.
• cycloheteroalkylthio refers to -SH.
• (cycloheteroalkyl)alkylthio refer to -SR, where R is optionally substituted loweralkyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, aralkyl, heteroaralkyl, (cycloalkyl)alkyl, and (cycloheteroalkyl)alkyl respectively.
• sulfonyl refers herein to the group -SO 2 -.
• heteroarylkylsulfonyl refers to -SO 2 R where R is optionally substituted loweralkyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, aralkyl, heteroaralkyl, (cycloalkyl)alkyl, and (cycloheteroalkyl)alkyl respectively.
• sulfinyl refers herein to the group -SO-.
• heteroarylkylsulfinyl refers to -SOR where R is optionally substituted loweralkyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, aralkyl, heteroaralkyl, (cycloalkyl)alkyl, and (cycloheteroalkyl)alkyl respectively.
• Formyl refers to -C(O)H.
• Carboxyl refers to -C(O)OH.
• Carbonyl refers to the divalent group -C(O)-.
• the terms “loweralkylcarbonyl”, “arylcarbonyl”, “heteroarylcarbonyl”, “cycloalkylcarbonyl”, “cycloheteroalkylcarbonyl”, “aralkycarbonyl”, “heteroaralkylcarbonyl”, “(cycloalkyl)alkylcarbonyl”, and “(cycloheteroalkyl)alkylcarbonyl” refer to -C(O)R, where R is optionally substituted loweralkyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, aralkyl, heteroaralkyl, (cycloalkyl)alkyl, and (cycloheteroalkyl)alkyl respectively.
• Thiocarbonyl refers to the group -C(S)-.
• Carbonyloxy refers generally to the group -C(O)-O-.
• loweralkylcarbonyloxy refers generally to the group -C(O)-O-.
• (cycloheteroalky ⁇ alkylcarbonyloxy) refer to -C(O)OR, where R is optionally substituted loweralkyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, aralkyl, heteroaralkyl, (cycloalkyl)alkyl, and (cycloheteroalkyl)alkyl respectively.
• Oxycarbonyl refers to the group -O-C(O)-.
• Carbonylamino refers to the group -NH-C(O)-.
• the present invention includes N- substituted carbonylamino (-NR'C(O)R), where R' is optionally substituted loweralkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl and R retains the previous defintion.
• Carbonylthio refers to the group -C(O)-S-.
• heteroarylkylcarbonylthio refers to -C(O)SR, where R is optionally substituted loweralkyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, aralkyl, heteroaralkyl, (cycloalkyl)alkyl, and (cycloheteroalkyl)alkyl respectively.
• methylene refers to an unsubstituted, monosubstituted, or disubstituted carbon atom having a formal sp.sup.3 hybridization (i.e., -CRR'-, where R and R' are hydrogen or independent substituents).
• the present invention provides a compound having the structure:
• R 1 and R 2 are selected independently from the group consisting of: hydrogen, halo, cyano, carbonyl, carboxyl, and optionally substituted lower alkyl, optionally substituted lower alkyloxy, and optionally substituted lower alkylcarbonyl.
• R 3 -R 6 are selected independently from the group consisting of: optionally substituted lower alkyl and lower hydroxyalkyl, and further R 3 and R 4 , and R 5 and R 6 , together with the nitrogens to which they are attached respectively, may form independently an optionally substituted saturated or unsaturated five- or six-membered ring.
• R 3 -R 6 is substituted or unsubstituted C 1 ⁇ alkyl, substituted or unsubstituted C 2 ⁇ alkenyl when both R 1 and R 2 are selected from the group consisting of hydrogen, C 1 -
• At least one OfR 1 and R 2 is hydrogen, and , in more specific embodiments of the foregoing, both R 1 and R 2 are hydrogen.
• At least one Of R 3 -R 6 ' together with the nitrogens to which they are attached respectively, is an optionally substituted saturated or unsaturated five- or six-membered ring; in more specific embodiments of the foregoing, the aforementioned five- or six-membered ring is saturated.
• Compound 1 just described are those in which the aforementioned saturated five- or six-membered ring is a five-membered ring. In yet more specific embodiments, the aforementioned saturated five-membered ring is pyrrolyl.
• R 1 and R 2 are selected independently from the group consisting of: halogen, carboxyl, carbonyl, and cyano.
• R 1 and R 2 are selected independently from the group consisting of: halogen, carboxyl, carbonyl, and cyano.
• R 2 are selected independently from the group consisting of: halogen, carboxyl, carbonyl, and cyano, at least one Of R 1 and R 2 is halo; and in still more specific embodiments, at least one OfR 1 and R 2 is chlorine or fluorine. In yet more specific embodiments, at least one OfR 1 and R 2 is fluorine, or at least one OfR 1 and R 2 is chlorine.
• R 1 and R 2 are selected independently from the group consisting of: halogen, carboxyl, carbonyl, and cyano
• Ri and R 2 are halo
• both R 1 and R 2 is halo
• more specific embodiments are those for which both R 1 and R 2 are chlorine or fluorine.
• Yet more specific embodiments of the latter are those in which both R 1 and R 2 are fluorine, those in which both R 1 and R 2 are chlorine, and those wherein one OfR 1 and R 2 is chlorine and the other of R 1 and R 2 is fluorine.
• each OfR 3 -R 6 is optionally substituted lower alkyl; and, more specifically, where each of R 3 -R 6 is optionally substituted methyl or optionally substituted ethyl; and, still more specifically, where each of R 3 - R 6 is methyl or ethyl; and, yet more specifically, where each of R 3 -R 6 is methyl.
• the invention provides the novel compound shown below:
• the invention provides the novel compound shown below:
• the invention provides the novel compound shown below:
• the invention provides the novel compound shown below:
• the invention provides the novel compound shown below:
• the compounds of the invention can be made using methods and materials well known to persons having ordinary skill in the art in combination with the present disclosure.
• embodiments of those compounds described by Compound 1 above for which R 1 and R 2 independently are hydrogen, alkyl, or halo, especially fluoro and chloro, and R 3 -R 6 independently are lower alkyl, especially methyl or ethyl, or form a pyrrolidyl ring with the respective nitrogen to which they are attached can be made by persons having ordinary skill in the art using the procedures described in published U.S. Patent Application Serial No. US 2006/0287523 Al, which is incorporated herein by reference in its entirety and for all purposes. Examples are provided in Section 4.3 below.
• the present invention provides a method for treating an animal infected with a virus, comprising administering to such animal a therapeutically effective amount of a compound having the structure:
• Ri and R 2 are selected independently from the group consisting of: hydrogen, halogen, cyano, carbonyl, carboxyl, and optionally substituted lower alkyl, optionally substituted lower alkyloxy, and optionally substituted lower alkylcarbonyl.
• R 3 -R 6 are selected independently from the group consisting of: optionally substituted lower alkyl and lower hydroxyalkyl, and further R 3 and R 4 , and R 5 and R 6 , together with the nitrogens to which they are attached respectively, may form independently an optionally substituted saturated or unsaturated five- or six-membered ring.
• the virus is selected from the group consisting of: HCV, VEEV, RVFV, LASV, and EBOV.
• the virus is HCV or VEEV; in more specific embodiments, the virus is HCV, and in other more specific embodiments, the virus is VEEV.
• the virus is LASV, RVFV or EBOV; in more specific embodiments, the is RVFV, in other more specific embodiments, the virus is EBOV, and in still other more specific embodiments, the virus is LASV.
• Figure IA shows the control group, which did not receive any compound.
• the control mice appear to be healthy through Day 3, but all show symptoms of stress ("ruffling") by Day 5. On Day 6 over half of the mice had died; and the other half were clearly sick with the virus. By Day 10 all mice in the control group were dead.
• Figure IB mice treated with the compound of the invention showed no symptoms thorough Day 5, some signs of stress between Day 6 and Day 9, and then fully recovered by Day 10. Thus, the compound of the invention provided complete prophylaxis to the study group.
• Figure 2A shows the control group, which did not receive any compound.
• the control mice appear to be healthy through Day 4, but all show symptoms of stress ("ruffling") by Day 5 and two mice had died. On Day 6 over all of the mice had died or were sick. By Day 7 all mice in the control group were dead.
• Figure 2B all mice treated with the compound of the invention showed no symptoms thorough Day 3. Two mice died, and the surviving mice showed stress on Day 4. By Day 6, four mice had died and the remaining six showed stress. But by Day 9, the surviving mice had recovered.
• the compound of the invention provided prophylaxis to 60% of the study group.
• novel compounds of the invention can be formulated and administered to patients using methods and materials known to persons having ordinary skill in the art. Similarly, the methods of the invention can be practiced using methods and materials known to persons having ordinary skill in the art.
• intermediate 2a or 2b (77.7 mmol) was dissolved in about 60 ml of 6N hydrochloric acid, and the solution was slowly added to about 20 ml NaNO 2 aqueous solution under ice bath. The resulting mixture was stirred at room temperature for about one hour. A yellow precipitate formed, which was collected and washed with cold 2N HCl and diethyl ether to give a substantially pure desired product 3a or 3b respectively. Yield: 3a: 8.2 g; 3b: 10.0 g.
• the precipitate (the crude product) was filtered, and purified chromatographically with silica gel column (several times), by eluting with CH 2 C1 2 /CH 3 OH (14: 1), followed by vacuum drying. Yield: 9.1 mg.
• test compound methylene blue, Dimethyl MB
• IP intraperitoneal injection
• test compound (Dimethyl MB) was dissolved in saline at 160 ⁇ g/ml and 100 ⁇ g/ml administered twice daily by IP, beginning at Day 2.
• mice were monitored daily for clinical signs, including ruffling, immobility. Mice were weighed each day and their weights recorded.
• mice in the control group i.e., untreated mice
• mice in the control group had noticeable morbidity by Day 3 and 100% mortality by Day 6.
• Mice treated with the compound showed morbidity starting on Day 3, but had recovered by Day 6, with a 100% survival.
• Vero cells were plated on 12- or 24-well plates. When the cells were 80%-90% confluent, they were infected with 100 pfu or 50 pfu respectively of VEEV Trinidad virus at 37°C for one hour with rocking every 15 minutes.
• the 12-well plates used 1 ml overlay for each well.
• the 24-well plates need 0.5 ml overlay for each well.
• Replicon potency and cytotoxicity [00101]Huh-luc cells (stably replicating the Bartenschlager I3891uc-ubi-neo/NS3-3'/ET genotype Ib replicon) were treated with serial dilutions of compound (DMSO was used as solvent) for 72 hours. Replicon copy number was measured by bioluminescence and non-linear regression was performed to calculate EC50s. Parallel plates treated with the same drug dilutions were assayed for cytotoxicity using the Promega CellTiter-Glo cell viability assay.
• Human-7 cells overexpressing CD81 (called Lun-CD81) were infected for ⁇ 8 days at which point most of the cells were infected (i.e. positive for HCV core protein) and are producing virus at ⁇ 103 focus forming units (ffu)/ml.
• the infected cells were seeded in 96 well and 24 well plates at a density of 5xlO3/well and 2.5xlO4/well, respectively. The next day, cells were washed 3x with PBS and compound dilutions (in complete DMEM) were added to each well. Cells were then incubated for 3 days at 37oC.
• RNA replication (EC 50 ) - 96 well plate was used for EC 50 analysis using a novel NS3 protease substrate assay.
• Virus production (EC 50 ) - Supernatants were removed from the 24 well plate and an end point limit dilution assay was performed in which na ⁇ ve cells were infected for an additional three days to quantitate the amount of infectious virus in the supernatant. Cells were then fixed with 4% paraformaldehyde and indirect immunofluorescence was performed using an anti-HCV core antibody. HCV -positive foci were counted at each compound dilution to calculate the EC50 value.
• Cytotoxicity (EC 50 ) - 96 well plate was used for EC 50 analysis using the Promega CellTiter-Glo assay.
• a 1% agarose (Ig agarose in 100 ml diH 2 0) was prepared and heated by microwave until agar was dissolved. The remaining solution was cooled to 45 0 C in the water bath during the incubation.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Virology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Communicable Diseases (AREA)
• Veterinary Medicine (AREA)
• Oncology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Molecular Biology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=39718949

Family Applications (1)

Country Status (7)

Cited By (8)

Families Citing this family (2)

Citations (3)

Family Cites Families (4)

• 2008
  • 2008-04-03 AU AU2008237276A patent/AU2008237276A1/en not_active Abandoned
  • 2008-04-03 US US12/062,491 patent/US8227459B2/en active Active
  • 2008-04-03 WO PCT/US2008/059326 patent/WO2008124550A1/en active Application Filing
  • 2008-04-03 CN CN200880008338A patent/CN101631780A/zh active Pending
  • 2008-04-03 EP EP08745055A patent/EP2137172A1/en not_active Withdrawn
  • 2008-04-03 CA CA2686513A patent/CA2686513C/en not_active Expired - Fee Related
  • 2008-04-03 JP JP2010502312A patent/JP2010523591A/ja active Pending

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events